The studies used patient samples and patient‐derived tumour models to show that SFX‐01 targets cancer stem cells ("CSC") in early and metastatic breast cancers and has the potential to overcome resistance to endocrine treatment in oestrogenreceptor positive ("ER+") breast cancers.
The studies also showed that SFX‐01 potently suppressed the elevated levels of phospho‐STAT3 ("STAT3") seen after endocrine treatment. Investigations are continuing into the role of STAT3 signalling effectors as part of this mechanism of action.
The poster, entitled SFX‐01 targets STAT3 signalling to inhibit stem‐like cells in breast cancer patient‐derived xenogra tumours, concludes that the study data "demonstrate the potential of SFX‐01 for clinically meaningful improvements to endocrine therapy in ER+ breast cancer by reversing CSC‐mediated resistance".
The lead authors of the poster are Dr Bruno Simões and Dr Rob Clarke. Dr Clarke, who led the studies, is a Reader in Breast Biology and is the Director of the Manchester Breast Cancer Now Research Unit at the University of Manchester.
A copy of the poster will be made available later today on Evgen Pharma's website, www.evgen.com.
Steve Franklin, CEO of Evgen Pharma, said "We are very excited by this data, which provides further evidence that SFX‐01's mechanism of action is to target cancer stem
cells to reverse the resistance to hormone treatment seen in ER+ breast cancer. I would like to thank Dr Clarke and his team for their on‐going work on SFX‐01. The team's work highlights the effect of SFX‐01 on STAT3, which is well known to play a key role
in tumour renewal and metastases.
"This mechanistic work supports our on-going Phase II clinical SFX‐01 in metastic breast cancer patients. We look forward to reporting interim update from the Phase II trial in the first half of this calendar year followed by the final readout around the year‐end."
Further details of the UK Interdisciplinary Breast Cancer Symposium 2018, 15‐16 January 2018, are available at this link: